Full View

pharmacological aspects of anti‐TNF biosimilars in inflammatory bowel diseases

V Jairath, K Gecse, R Khanna… - Alimentary …, 2015 - Wiley Online Library
Background Anti‐tumour necrosis factor (anti‐TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …
被引用次数：75 相关文章

pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

K Papamichael, T Van Stappen… - Alimentary …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Anti-tumour necrosis factor (anti-TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …

pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases

K Papamichael, T van Stappen… - Alimentary …, 2015 - researchinformation.amsterdamumc …
Anti-tumour necrosis factor (anti-TNF) monoclonal antibodies have shown efficacy in
inflammatory bowel diseases (IBD). As these therapies lose patent protection, biosimilar …

pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.

K Papamichael, T Van Stappen, V Jairath… - Alimentary …, 2015 - europepmc.org
Background Anti-tumour necrosis factor (anti-TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …

pharmacological aspects of anti‐TNF biosimilars in inflammatory bowel diseases

K Papamichael, T Van Stappen, V Jairath… - Alimentary …, 2015 - infona.pl
Background Anti‐tumour necrosis factor (anti‐TNF) monoclonal antibodies have shown
efficacy in inflammatory bowel diseases (IBD). As these therapies lose patent protection …